About

Our primary focus is on the development of novel therapeutics and platforms. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We invest in North America, Europe, Israel and Asia/Pacific with approximately USD 800 million under management in committed capital and more than 24 portfolio companies.

Key facts

At-a-glance profile data

Website: novartis.com
Type: Corporate Venture Capital
Headquarters: Switzerland
Funds raised: $800M
Portfolio companies: 3
Stages: Series B
Series F
Cheque size: $5M to $30M
Sector focus: Healthcare
Drug Development
Genomics
Next Generation Sequencing
Biotech

Recent investments

Recent funding rounds Novartis Venture Fund took part in
Date	Company	Round	Amount
23 Aug 2023	80073	Series D	$75M
21 Sept 2020	80073	Series C	$57M
28 May 2019	Ayala Pharmaceuticals	Series B	$30M
19 Jun 2017	Gamida Cell	Series G	$40M
15 Oct 2015	Gamida Cell	Series F	$5M
19 Aug 2014	Gamida Cell	Series F	$35M

Add first review

Frequently asked

What companies has Novartis Venture Fund invested in?

Novartis Venture Fund has invested in 80073, Ayala Pharmaceuticals, Gamida Cell, FORE Biotherapeutics.

AUM

$800M

PORTFOLIO